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Background: miRNA-184 is an oncogene in human hepatocellular carcinoma but acts as a tumor suppressor in
tongue squamous cell carcinoma. Studies have shown that miR-184 was down-regulated in glioma and TNFα-induced
protein 2 (TNFAIP2) was closely related to tumorigenesis. This study aimed to determine the functions of miR-184 in
glioma and the mechanisms of miRNA-184-TNFAIP2 mediated glioma progression.
Methods: Real-time reverse-transcription PCR detected expression of miR-184 and TNFAIP2. U87 and U251 cells were
transfected with miR-184 mimic, inhibitor, or negative control miRNA, and their invasion abilities were assayed. Cellular
proliferation was measured by the cell counting kit-8 assay. miR-184 effects on glioma cell apoptosis and cell cycle were
assessed by flow cytometer. Biological information software have predicted that miR-184 could target TNFα-induced
protein 2 (TNFAIP2), Which was further validated by Western blot and qRT-PCR in glioma cells. In vivo, U87 cells
transduced with either lentiviral over-expressed miR-184 or control lentivirus were injected into nude mice
subcutaneously and intracranial respectively.
Results: Expression of miR-184 was significantly lower in glioma tissues and cell-lines compared to normal brain tissues.
Protein and mRNA expression of TNFAIP2 were inversely correlated with miR-184 in glioma. In vitro, proliferation and
invasion abilities were also decreased in U87 and U251 cells after transfection with miR-184 mimic. In vivo, the
xenografted tumor size in the miR-184 overexpressing group were smaller than the miR-NC group. Concordantly, U87
and U251 cells transfected with miR-184 mimic had a higher apoptosis rate, triggering an accumulation of cells at the
G0/G1 phase and decreased cells in S-phase.
Conclusions: miR-184 could regulate TNFAIP2 expression and affected its translation in glioma. miR-184 could also
inhibit glioma progression and might serve as a novel therapeutic target in glioma.
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Gliomas are the most common and lethal primary brain
tumors in adults. Patients with newly diagnosed glio-
blastoma multiforme (GBM), the most malignant histo-
logical subtype of glioma, have a median survival period
of approximately one year [1-3]. Despite comprehensive
therapies including surgical resection, radiation, and* Correspondence: zhouyouxin@suda.edu.cn
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unless otherwise stated.chemotherapy, the final prognosis of glioma remains ex-
tremely bad [4]. The significant property of a glioma
usually develops in the craniocerebral depths and always
infiltrates into adjacent normal brain tissue, so complete
resection is difficult finished and very dangerous for pa-
tients with gliomas [5]. Therefore, novel biological mo-
lecular therapies that inhibit tumor cell growth and
invasion are urgently needed.
MicroRNAs are endogenous small noncoding RNAs
with lengths of approximately 18–25 nucleotides. They
regulate gene expression at the transcriptional and post-
transcriptional level by completely or incompletelyThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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target gene messenger RNA (mRNA) and by repressing
the translation or promoting the degradation of the tar-
get gene to exert biological functions [6-8]. There is
mounting evidence confirming that microRNAs play
pivotal roles in tumorigenic processes including cellular
differentiation, proliferation, angiogenesis, cell death,
apoptosis, and invasion [9]. MicroRNAs will hopefully
be applied in clinical cancer diagnosis, therapy, and
prognosis [10]. miR-184 is particularly enriched in the
brain and testes in humans and is located in region 25.1
on the q-arm of chromosome 15. Its corresponding
transcript is comparatively small (84 bp) and is not
encoded near other clustered miRNAs [11,12]. Recently,
researchers have shown that miR-184 functions as a po-
tential oncogene in human hepatocellular carcinoma by
suppressing Sox7 expression [13]. The overexpression of
miR-184 might play an onco-miRNA role in the anti-
apoptotic and proliferation processes. The plasma expres-
sion levels of miR-184 were also associated with the
presence of primary tumors and might be used as a novel
cancer marker in tongue squamous cell carcinoma [14].
However, the high expression of miR-184 reportedly
causes a decrease in cell numbers and increases apoptosis
in neuroblastoma cell-lines [15]. In concordance with the
previous results, Tivnan et al. have demonstrated that
miR-184 mediated inhibition tumor growth and prolonged
the survival time in an orthotopic murine model of neuro-
blastomas [16]. However, miR-184 functions both as onco-
gene and tumor suppressor in the development and
progression of numerous cancers. For glioma, miR-184 ex-
hibited a progression-associated down-regulation miRNA;
Overexpression of miR-184 in A172 and T98G glioma
cells significantly decreased cell viability and proliferation
[17]. Besides, a study by Emdad et al. confirmed that miR-
184 is down-regulated in human malignant glioma cells
and tumor tissue as compared with their non-neoplastic
counterpart [18]. The functions and exact mechanisms of
miR-184 in glioma are poorly uderstood.
TNFα-induced protein 2 (TNFAIP2) maps to chromo-
some 14q32, encodes a 654 amino acid protein, belongs to
the Sec6 family, is differentially expressed in capillary
tube-like formation in vitro, and can be induced to express
itself with a TNFα treatment [19]. TNFAIP2 was highly
expressed in marrow from patients with acute myeloge-
nous leukemia subtypes M0-M2 but was repressed in
marrow cells from M3 patients. It was also a target gene
of PML-RARs (promyelocytic leukemia-retinoic acid re-
ceptor α) in APL (acute promyelocytic leukemia) [20].
Recently, Chen et al. found that TNFAIP2 is highly
expressed in tumor cells compared to adjacent normal tis-
sue, is closely related to invasion and metastasis, and may
serve as an independent prognostic indicator for nasopha-
ryngeal carcinoma (NPC) [21]. A previous study showedthat miR-184 directly targeted the 3′-UTR of TNFAIP2
using a dual-luciferase reporter assay in lung, head, and
neck cancer cell-lines. The miR-184 binding site single nu-
cleotide polymorphisms [SNP (rs8126 T > C)] in the 3′-
UTR of TNFAIP2 modulated TNFAIP2 expression and
contributed to susceptibility to squamous cell carcinoma
of the head and neck (SCCHN) [22].
The expression and function of TNFAIP2 have not been
studied in gliomas; the relationship between TNFAIP2
and miR-184 also has not been studied. This study con-
firmed that miR-184 was lower in glioma cell-lines and in
49 glioma specimens than in normal brain tissues. The
up-regulation of miR-184 inhibited glioma cell prolifera-
tion and invasion and induced apoptosis. It also increased
the cell population in the G0/G1 phase and reduced the
percentage of U87 and U251 cells in the S phase. The ex-
pression of TNFAIP2 was higher in 81 glioma samples
compared to noncancerous brain tissues. The results of
this experiment implied that miR-184 might be a suppres-




Tissue samples were obtained from March 2009 and
September 2011 from the Department of Neurosurgery
of the First Affiliated Hospital of Soochow University.
There were a total of 81 glioma samples (29 cases low-
grade WHO grades I and II, 52 cases high-grade WHO
grades III and IV) and 8 non-neoplastic brain tissues ob-
tained from patients who suffered severe cerebral injury.
Their injuries required a reduction in increased intracra-
nial pressure by removing a partial amount of normal
brain tissue. The mean age of the patients at the time of
surgery was 48.9 years for 31 women and 49.76 years for
50 men. There were 2 cases of pilocytic astrocytoma
(grade I), 22cases of diffuse astrocytoma and 5 cases of
pleomorphic xanthoastrocytoma (grade II), 19 cases of
anaplastic astrocytoma and 5 cases of oligoastrocytoma
(grade III), 28 cases of primary brain glioblastoma (grade
IV). All tissue specimens were immediately collected
and stored in liquid nitrogen after resection. This study
was authorized by the local ethics committee of our hos-
pital. All patients were informed of their participation in
the study before surgery and gave their consent.
Cells and cell culture
The glioma cell-lines U87, U373, U251, and A172 were
purchased from the Cell Bank Type Culture Collection
of the Chinese Academy of Sciences (Shanghai, China).
U373 cells were retired from the ATCC catalogue, since
similar characteristics were found between U373 and
U251 cells. SHG44 and normal human astrocyte 1800
cells were conserved and provided by our Brain and
Figure 1 miR-184 was down-regulated in human glioma tissues and glioma cell-lines. A. shows the qRT-PCR analysis results of miR-184
expression in glioma tissues and normal brain tissues (NBT). It showed that miR-184 expression in 49 gliomas was markedly lower than in 8
non-cancerous brain tissues and decreased with the increasing degree of malignancy in gliomas (low grade vs high grade). U6 small nuclear RNA
was used as an internal control. B. shows that miR-184 expression in 5 glioma cell-lines was down-regulated compared to 6 normal brain tissues
(N1, N2, N3, N4, N5, N6) .U6 small nuclear RNA was used as an internal control. Data are shown as mean + s.d. (n = 3); *indicates P-value <0.05,
**indicates P-value <0.01.
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in Dulbecco’s modified eagle’s medium (DMEM, Hyclone,
Thermo Fisher Scientific, Waltham, MA, USA) supple-
mented with 100 U of penicillin/ml, 100 mg of strepto-
mycin/ml, and 10% fetal bovine serum (FBS, Gibco) at 37°C
under a humidified atmosphere of 5% CO2.Transfection
U87 and U251 cells were transfected with miR-184 mimic,
miR-184 inhibitor, and their corresponding negative con-
trol (miR-NC and anti-NC) by Lipofectamine2000 (Invi-
trogen Inc., Carlsbad, CA, USA), which were designed and
synthesized by Invitrogen. The sequences were as follows:
Table 1 2-ΔΔCT values of miR-184 expression in 57 cases
(normalized to U6)
Noncancerous samples Glioma samples P value
Low grade High grade
(n = 8) (n = 16) (n = 33)
1.1772 ± 0.55268 P1 = 0.003
0.3057 ± 0.2197 P2 = 0.001
0.0945 ± 0.31666 P3 = 0.002
2-ΔΔCT values of miR-184 and U6 were detected by real-time quantitative PCR.
P1(Noncancerous VS Low grade), P2(Noncancerous VS High grade), P3(Low
grade VS High grade).




5′-ACCCUUAUCAGUUCUCCGUCCA-3′; and the nega-
tive control (anti-NC), 5′-CAGUACUUUUGUGUAGUAC
AA-3′. Mock group was untreated by anything. To achieve
stable transfectant overexpression of miR-184 and negative
control oligonucleotide, pLenti-miR-184-GFP and pLenti-
NC-GFP (Genechem Co., Ltd., Shanghai, China) were ap-
plied to transfect U87 cells.
Quantitative RT-PCR
RNA was extracted using TRIzol reagent (Invitrogen
Inc., Carlsbad, CA, USA), which was quatified by spec-
trophotometer . Only the RNA samples with 260/280 ra-
tios of 1.8–2.0 were used for further investigation. The
miR-184 expression level was measured using All-in-
One™miRNA qRT-PCR Detection Kit (GeneCopoeia,
Rockville, MD, USA) according to the instructions.
Briefly, 100 ng RNA was used to synthesize cDNA in a
25 μl reaction system containing 5 μl 5× Reaction Buffer,
1 μl RTase Mix, and 1 μl 2.5 U/μl Poly A Polymerase.
All reaction systems were incubated at 37°C for 60 min
and 85°C for 5 min. The PCR conditions for miRNA
quantification were as follows: 10 min at 95°C, then
40 cycles of 10 s at 95°C, 20 s at 62°C, and 30 s at 72°C.
The relative level of TNFAIP2 mRNA was examined
using SYBR green qRT-PCR (Applied LightCycler480).
Subsequently, 2 μg of total RNA were reverse
transcribed in a 20 μl reaction containing 10 units of M-
MLV reverse transcriptase and 0.5 μg of oligo (dT) pri-
mer. A total of 2 μl of cDNA was used for qPCR. The
expression level of GAPDH was used as an internal control
for mRNAs , and the endogenous U6 snRNA as an internal
control for miRNAs. The following primers were used:
TNFAIP2 forward primer, 5′-CCTGCTCTCCCTACGC-3′,
reverse primer, 5′-CGTCCAAGATGCTCCG-3′ [19]; and
GAPDH forward primer, 5′-AACGGATTTGGTCGTA
TTG-3′, reverse primer, 5′-GGAAGATGGTGATGGGA
TT-3′. The PCR conditions for relative quantification were
as follows: initial denaturation at 95°C for 5 min, then 40 cy-
cles consisting of 95°C for 10 s, 60°C for 30 s, and 72°C for
30 s. The relative expression of each gene was calculated
and normalized using the 2−ΔΔCt method. Each sample was
tested in triplicate.
Cell proliferation, cell cycle, and cell apoptosis
Cell proliferation was measured by a cell counting kit-8
(CCK-8) (Beyotime, Shanghai, China). Cells (2 × 103 per
well) were seeded in a 96-well plate and incubated for
24 h. Then, the cells were transfected with miR-184
mimic, miR-184 inhibitor, or the negative control
miRNA (Negative)at a final concentration of 50 nmol/L.CCK-8 (10 μl) was added to each well at 24, 48, and
72 h after transfection, and plates were incubated for 4 h
at 37°C. Absorbance was measured at a wavelength of
450 nm. For cell cycle analysis, transfected cells were fixed
in 75% ethanol at 4°C and stained with propidium iodide
(PI). The cell cycle distribution was analyzed by flow cyt-
ometer (CYTOMICS, FC, 500 Beckman-coulter, CA,
USA). Cell apoptosis was also detected using the Annexin
V PE Apoptosis Detection Kit PE (eBioscience, San Diego,
CA, USA) by flow cytometer. Cells transfected with miR-
184 mimic, inhibitor, or negative control miRNA were
collected and resuspended in 400 μl of 1× binding buffer
containing 5 μl 7-AAD (7-amino-actinomycin D) and 5 μl
PI at room temperature in the dark for 10–15 min. All ex-
periments were performed in triplicate.
Wounding healing and invasion assay
For the cell migration and cell invasion assay, all the
cells (U87, U251) were used after transfection. For the
cell motility assay, cells were seeded in six-well plates
and cultured to 70-80% confluence. A 200 μl pipette tip
was applied to generate a linear wound. The floating
cells were rinsed with culture medium. Cells cultured
for 48 h and were recorded under a microscope (Olym-
pus, Tokyo, Japan) at 0, 6, 12, 24, and 48 h. For the cell
invasion assay, Transwell chambers were covered with
Matrigel (BD Bioscience, San Jose, CA, USA), and 1 ×
105 cells suspended in 100 μl serum-free medium were
added to the upper chambers. The lower chambers were
filled with 750 μl DMEM with 10% fetal bovine serum.
After 48 h of incubation, non-invading cells on the
upper surface of the membrane were removed using a
cotton swab. The invaded cells were fixed in 4% formal-
dehyde for 30 min and stained with 0.1% crystal violet
for 5 min. Then, cells were imaged and counted under a
microscope. The number of cells that penetrated the
Matrigel was counted from 6 randomly selected fields.
Western blotting
Total protein was isolated by RIPA and quantified using a
BCA (bicinchonininc acid) assay kit (Beyotime, Shanghai,
Figure 2 TNFAIP2 expression was up-regulated in 81 glioma tissues and 5 glioma cells. A. shows that the expression levels of TNFAIP2 in
81 human glioma tissues were higher than in 5 non-cancerous brain tissues normalized to GAPDH. TNFAIP2 expression was higher in high-grade
gliomas (WHO grades III and IV) than in low-grade gliomas (WHO grades I and II). B. shows that the expression levels of TNFAIP2 mRNA in 5
glioma cell-lines were higher than in5 non-cancerous brain tissues. C. The left panel shows the Western blot results, which further confirmed that
the expression level of TNFAIP2 protein was higher in glioma cell-lines than in normal human astrocyte 1800 cells. The right panel shows the
relative expression of TNFAIP2 protein in glioma cells, as depicted in the histogram. Data are shown as mean + s.d. (n = 3); *indicates P-value <0.05,
**indicates P-value <0.01.
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rated by 12% SDS-PAGE and transferred into nitrocel-
lulose membranes. After blocking, the membranes
were incubated with primary antibodies overnight at
4°C. After washing, membranes were incubated with
HRP-conjugated anti-rabbit secondary antibodies at a
dilution of 1:4000 (Prosci Inc., Poway, CA, USA) atroom temperature for 2 h. Then, the membranes were
detected and recorded using ECL Western blotting de-
tection reagents. The primary antibodies used were
rabbit anti-TNFAIP2 at a dilution of 1:1000 (Santa
Cruz Biotechnology, Santa Cruz, CA, USA) and rabbit
anti-GAPDH at a dilution of 1:2000 (Abcam, Tokyo,
Japan).
Table 2 2-ΔΔCT values of TNFAIP2 mRNA expression in 86
cases (normalized to GAPDH)
Noncancerous
samples
Glioma samples P value
Low grade High grade
(n = 5) (n = 29) (n = 52)
1.5905 ± 1.62443 P1 = 0.042
5.0454 ± 3.55360 P2 = 0.001
7.4272 ± 3.72806 P3 = 0.006
2-ΔΔCT values of miR-184 and U6 were detected by real-time quantitative PCR.
P1(Noncancerous VS Low grade), P2(Noncancerous VS High grade), P3(Low
grade VS High grade).
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To select stably expressed cells, U87 cells were transfected
with pLenti-miR-184-GFP or pLenti-NC-GFP. U87-miR-
184 and U87-miR-NC cells were established and inocu-
lated into nude mice (4 to 5 weeks old) in intracranial
(1 × 105) and subcutaneous (1 × 106) fashions, respectively
(n = 6 /group). Caliper measurements were performed to
assess tumor growth. The size is represented by the width
of subcutaneous tumor multiply the length of subcutane-
ous tumor (W*L). MRI (Magnetic Resonance Imaging)
was also used to observe tumor growth. Each nude mouse
was anesthetized by 200 μl 4% chloral hydrate, then
scanned by Signa HDX model 3.0 T. MRI machine (GE.,
Detroit, USA). T2-weight images were acquired, and the
following parameters were used: repetition time 2160.00
milliseconds, echo time 108.80 milliseconds, field of view
10 × 10 cm, and matrix 256 × 256. About 5 weeks post-
implantation, the nude mice were euthanized and the tu-
mors obtained. All mice experimental procedures were
performed according to the First Affiliated Hospital of
Soochow University policies.
Immunohistochemistry
Formalin-fixed paraffin-embedded U87 intracranial tu-
mors were cut into 6-μm-thick sections on a microtome.
Immunohistochemical staining was performed according
to standard procedures. Antigen retrieval was conducted
in 0.1 M citrate buffer (pH 6.0) at 95°C for 16 min and
cooled at 25°C for 1 h. After blocking, slides were incu-
bated with primary antibodies TNFAIP2 (1:200, Santa
Cruz Biotechnology, Santa Cruz, CA, USA), SOX2 (1:200,
Boster Bioengineering Co., Wuhan, China) and ki-67
(1:200, Boster Bioengineering Co., Wuhan, China). Next,
according to the manufacturer’s instructions, slides were
treated with the Cell & Tissue Staining Kit HRP-DAB sys-
tem (R&D Systems, Minneapolis, MN, USA). The immu-
nohistochemical staining results were evaluated by two
experienced pathologists.
Statistical analysis
Statistical analyses were performed using GraphPad
PRISM4.0 software (GraphPad, La Jolla, CA, USA) and
SPSS version 13.0 (SPSS, Chicago, IL, USA). Experimen-
tal data are all presented as the means ± standard devi-
ation (SD). Statistical analyses were performed using a
two-tailed Student’s t-test or ANOVA and P < 0.05 was
considered statistically significant.
Results
The expression level of miR-184 was low in 49 cases of
glioma and 5 glioma cell-lines
Previous studies have shown that miR-184 was down-
regulated in glioma cell-lines and tissues and decreased
with the increasing degree of malignancy [17,18], buttoo few cases were studied. To confirm the results of the
present study, the number of glioma cases was increased
to detect the expression of miR-184. Quantitative reverse
transcriptase PCR (qRT-PCR) results demonstrated that
miR-184 expression in 49 glioma tissues was markedly
lower than in 8 noncancerous brain tissues and de-
creased with the increasing degree of malignancy in gli-
omas (low-grade vs high-grade, P < 0.01, Figure 1A,
Table 1). Meanwhile, miR-184 expression was also exam-
ined in glioma cell-lines (U87, U251, U373, A72,
SHG44). As demonstrated in Figure 1B, the expression
of miR-184 was significantly reduced in 5 glioma cell-
lines compared to 6 non-tumor brain tissues. These re-
sults suggested that low expression of miR-184 might be
associated with the malignant glioma process and might
act as a tumor suppressor in gliomas.
The expression of TNFAIP2 was high in glioma cells
and tissues
TNFAIP2 expression and its correlation with miR-184 in
gliomas have not been previously reported. QRT-PCR
results showed that the mRNA expression level of
TNFAIP2 was up-regulated in 5 glioma cell-lines com-
pared to 5 normal brain samples (Figure 2B), and highly
expressed in 81 glioma tissues (WHO grade I, 2 cases; II,
27 cases; III, 24 cases; and IV, 28 cases) compared to non-
neoplastic brain tissues (Figure 2A, Table 2). Western blot-
ting results further confirmed that the expression level of
TNFAIP2 protein was higher in 5 glioma cell-lines than in
normal human astrocyte 1800 cells (Figure 2C). Therefore,
the expressions of miR-184 and TNFAIP2 were negatively
correlated in gliomas.
Up-regulation of miR-184 directly regulated the low
expression of TNFAIP2 in human glioma cells
Biological information software (Targetscan, miRwalk,
miRanda) have predicted that TNFAIP2 was one of the
miR-184 target genes (Figure 3B) and have character-
ized TNFAIP2 as a direct target of miR-184 by a dual-
luciferase reporter assay in lung cancer cells [22]. To
Figure 3 The expression of miR-184 in U87 and U251 cells after transfection modulated the expression of TNFAIP2. A. To keep a high
transfection efficiency, qRT-PCR was used to detect the expression of miR-184 in U87 and U251 cells 48 h after transfection with miR-184 mimic,
inhibitors, and the negative control miRNA. U6 was used as the loading control. B. shows the bioinformatic analysis using Targetscan, miRwalk,
and miRanda, which predicted that miR-184 targeted TNFAIP2. C. shows the left panel, in which the Western blot analysis showed that miR-184
inhibited the expression of TNFAIP2 compared with the Mock group or the negative control miRNA group. The right panel shows the relative
expression of TNFAIP2 protein in glioma cells, as depicted in the histogram. The protein expression levels were normalized to GAPDH. D. depicts
the results of the qRT-PCR analysis, which showed that miR-184 inhibited the mRNA expression of TNFAIP2 in U87 and U251 cells compared with
their corresponding negative control. GAPDH was used as the loading control. Data are shown as mean + s.d. (n = 3); *indicates P-value <0.05,
**indicates P-value <0.01.
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sion in gliomas, U87 and U251 cells were infected with
miR-184 mimic, inhibitor , negative control miRNA.
Figure 3A shows that the expressions of miR-184 inU87 and U251 cells after transfection were detected by
qRT-PCR. The miR-184 expression level was signifi-
cantly increased after transfection with miR-184 mimic,
while its expression was decreased after transfection
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tive control (miR-NC and anti-NC). TNFAIP2 was mea-
sured both by qRT-PCR and Western blotting. The data
showed that the up-regulation of miR-184 led to the obvi-
ously down-regulated expression of TNFAIP2 and reduced
the expression of miR-184 resulted in the significant up-
regulation of TNFAIP2 (Figure 3C-D). Therefore, bothFigure 4 miR-184 reduced glioma growth and TNFAIP2 expression in
subcutaneous tumor growth at days 25 and 35 in U87-miR-184 and U87-N
miR-184 reduced glioma growth in the subcutaneous glioma nude mice m
miR-184 reduced glioma growth in the encephalic glioma nude mice mod
in vivo mice model. Data are shown as mean + s.d. (n = 3); *indicates P-valuTNFAIP2 mRNA and protein expressions were down-
regulated by ectopic miR-184 in glioma cells. The immu-
nohistochemical staining results also showed that the
glioma xenografts of the U87-miR-184 group expressed
less TNFAIP2 than the tumors in the U87-negative group
(Figure 4F). These collective results suggested that
TNFAIP2 is a genuine target of miR-184 in gliomas.vivo in the mice model. A. shows the T2-weighted MRI imaging of
egative nude mice (red arrows indicate tumors). B.-D. show that
odel. E. shows the representative H&E staining, which revealed that
el. F. shows that miR-184 reduced TNFAIP2 and ki-67 expression in an
e <0.05, **indicates P-value <0.01.
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migration of U87 and U251 cells
To further study the invasion and migration ability of
miR-184, Wound healing and Matrigel invasion assays
were performed. The wound healing assay showed that
miR-184 expression reduced the wound closure speed ofFigure 5 Up-miR-184 reduced the invasiveness and growth of glioma
U251 cells transfected with miR-184 mimics or inhibitor. The overexpressio
compared with the Negative group or inhibitor group. B. Transwell assay s
mimics or inhibitor. which revealed that the numbers of invasive cells were
group. Each bar represents the mean values from three independent expe
C. shows the cell survival, which was determined by the CCK-8 assay. Cell p
transfection with miR-184. Data are shown as mean + s.d. (n = 3); *indicatesU87 and U251 cells compared with negative control
oligonucleotide (Negative) and anti-miR-184 groups.
Contrarily, wound closure speed was improved by trans-
fection with miR-184 inhibitor compared with Negative
and miR-184 groups (Figure 5A). In accordance with the
results of the wound healing assay, the Transwell matrixcells. A. Wound healing assay shows that the migration of U87 and
n of miR-184 inhibited the wound closure speed of U87 and U251 cells
hows the invasion of U87 and U251 cells transfected with miR-184
significantly reduced compared with the Negative group or inhibitor
riments. The invaded cells were counted from 6 random fields.
roliferation was dramatically decreased in U251 and U87 cells after
P-value <0.05, **indicates P-value <0.01.
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miR-184 markedly suppressed the invasiveness of U87
and U251 cells compared to Negative and anti-miR-184
groups (Figure 5B). These findings suggested that miR-
184 inhibited the migration and invasion of U87 and
U251 cells in vitro.Up-regulation of miR-184 suppressed glioma cell
proliferation in vitro and in vivo, induced apoptosis,
and inhibited the cell cycle
As shown in Figure 5C, the CCK-8 assay was performed
to detect the effects of miR-184 on U87 and U25 cells
growth in vitro. The data demonstrated that the growth
curve was significantly inhibited in the miR-184 mimic-
transfected cells compared to the negative control
groups, and there was a significant difference between
the control (miR-NC)group and miR-184 group (Table 3).
To illustrate the mechanisms how miR-184 modulates
glioma cell growth, flow cytometry was applied to detect
the effects of miR-184 on cell apoptosis and the cell
cycle. The results indicated that the proportion of apop-
tosis cells transfected with miR-184 was significantly
higher than in the anti-miR-184 group and the negative
group (Figure 6A). Moreover, miR-184 induced U87 and
U251 cells cycle arrest and could increase the cell popu-
lation in G0/G1 phase and reduce the percentage of cells
in S-phase compared to the negative group (Figure 6B).
The role of miR-184 in growth was next explored
in vivo. The stable expression of U87 cells of miR-184 or
miR-NC were established through a lentivirus infection
method and inoculated into nude mice in intracranial
and subcutaneous, respectively. The immunohistochemi-
cal (IHC) results of SOX2 was used to ensure that U87
cells grow and form an intracranial tumor (Additional
file 1). As shown in our experiments, tumors were effi-
ciently suppressed in miR-184 group compared to nega-
tive group (Figure 4A). Representative intracranial H&E
stainings of xenograft tumors in nude mice showed that
miR-184 reduced glioma growth, as shown in Figure 4E.
The tumor size of the xenografts further confirmed that
the U87 miR-184 overexpression group showed slower
tumor growth than the U87 negative control group
in vivo. The IHC results of the nude mice intracerebralTable 3 Absorbance were measured at 450 nm of U87 and U2
Time U87 P
valuemiR-NC miR-184
24 h 0.2798 ± 0.1250 0.1266 ± 0.0175 0.167
48 h 1.1602 ± 0.1443 0.4917 ± 0.0705 0.002
72 h 1.5997 ± 0.0920 0.7066 ± 0.1102 0.000
U87and U251 cells were transfected with miR-184 mimic or miR-NC, and cell count
by the Studentns t-test.transplantation tumors also showed that U87 cells trans-
fected with miR-184 had reduced ki-67 expression com-
pared to the control group. The average expression rate
of Ki-67 is only 33% in U87 -miR-184 group, 75% in
U87 negative group (p < 0.01) (Figure 4F).Discussion
MiRNAs directly modulate and inversely regulate different
genes via inducing mRNA cleavage or translation repres-
sion and function as oncogenes or tumor suppressors de-
pending on the target genes [23,24]. Accumulated evidence
shows that miRNAs play a pivotal role in the development
of the malignant phenotype of glioma cells, including cell
survival, proliferation, angiogenesis, differentiation, and
stem cell generation [25]. The effects of miR-184 on malig-
nant progression are debated because it can act as a tumor
promoter or suppressor in some solid tumors [14,13,26].
Previous experimental studies have demonstrated that
miR-184 acted as a modulator in the malignant progres-
sion of gliomas [17] and was expressed lower in glioma
cells and tissues [18]. The collective data provided suffi-
cient indication that miR-184 might serve as a tumor sup-
pressor gene in gliomas. Gliomas are characterized by high
invasion, migration, and proliferation abilities [27], so it is
necessary to study the molecular mechanisms of miR-184
modulate gliomas. Even though previous studies have con-
firmed that miR-184 was down-regulated in gliomas and
decreased with the increasing degree of malignancy, the
number of cases used was too limited. The present study
increased the glioma cases to further confirm the expres-
sion and function of miR-184 in gliomas.
The present study’s results were in accordance with
those from previous studies. The miR-184 expression
levels were determined in 49 glioma tissues and 5 glioma
cell-lines by qRT-PCR analysis, which displayed a re-
markable down-regulation of miR-184 in gliomas com-
pared to 6 non-tumor brain tissues. Also, miR-184
down-regulation might be linked to glioma development.
Wound healing and Matrigel invasion assays were per-
formed to conclude that the overexpression of miR-184
markedly suppressed the invasiveness of U87 and U251
cells in comparison with the negative control group.
miR-184 performed an important function in glioma51
U251 P value
miR-NC miR-184
0.2790 ± 0.0086 0.2093 ± 0.0072 0.000
0.7397 ± 0.1150 0.4777 ± 0.0438 0.021
1.4623 ± 0.1166 0.8495 ± 0.0570 0.001
s were detected using CCK-8. The difference between two groups was analyzed
Figure 6 miR-184 overexpression induced apoptosis and increased the cell population in the G0/G1 phase. A. shows that miR-184
overexpression induced apoptosis in U87 and U251 cells and down-regulated of miR-184 reduced apoptosis compared with Negative group. The
left panel shows representative pictures of up-miR-184, which increased the apoptosis of U87 and U251 cells. The right panel shows the relative
number of apoptosis cells. B. shows the left panel, in which representative pictures show that miR-184 increased the cell population in the G0/G1
phase and reduced the percentage of cells in the S phase compared with the Negative group. The right panel shows the quantitative data of
cells in different cell cycle phases. Data are shown as mean + s.d. (n = 3); *indicates P-value <0.05, **indicates P-value <0.01 VS Mock.
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found to be significantly inhibited by the forced expres-
sion of miR-184. In vivo, the growth curve of tumor xe-
nografts showed that high expression level of miR-184
obviously slowed tumor growth. Foley et al. found that
miR-184 ectopic overexpression in neuroblastoma cell-
lines had pro-apoptotic and anti-proliferation functionsthrough inhibiting AKT2, which was one downstream
gene of the PI3K/AKT pathway [28]. Whether miR-184
inhibits glioma survival by blocking the PI3K/AKT2
pathway needs further investigation. The present study
identified that miR-184 induced the apoptosis of U87
and U251 cells, increased the cell population in the G0/
G1 phase, and reduced the percentage of cells in the S
Cheng et al. Journal of Experimental & Clinical Cancer Research  (2015) 34:27 Page 12 of 13phase. It is reasonable to hypothesize that miR-184
inhibited the proliferation of glioma cells by increasing
the percentage of early apoptotic cells, and it was sug-
gested that miR-184 might be a novel specific biomarker
for gliomas. In additional, Yuan et al. reported that miR-
184 was significantly upregulated in human glioma cells.
Our results differ from those by presented in the study
by Yuan et al. [29]. It is reasonable to hypothesize that
these differences are due to gliomas cell lines may have
undergone mutations during culture.
Biological information software also predicted that miR-
184 could directly target TNFAIP2 mRNA sequences at
the region from 1870 to 1876. In gastric cancer and
SCCHN, miR-184 bonded to the 3′-UTR of TNFAIP2,
and the miR-184 binding site single nucleotide polymor-
phisms in TNFAIP2 contributed to tumor susceptibility
[22,30]. TNFAIP2, which can be induced by treatment of
TNF-α that with miR-184 can directly target TNFAIP2 in
carcinoma (NPC) tissues, and is closely related to invasion
and metastasis and poor survival in NPC patients [21]. A
previous study demonstrated that latent membrane pro-
tein 1 (LMP1), an Epstein-Barr virus oncoprotein, induced
TNFAIP2 expression via NF-κB pathway and TNFAIP2
also contribute to LMP1-induced cell motility [31]. Re-
searchers have suggested that TNFAIP2 may play multiple
roles in the development of cancer and may be particularly
closely related to tumor metastasis. However, the bio-
logical function and molecular mechanism of TNFAIP2 in
gliomas remain unclear. The present study is first to re-
port that both mRNA and protein expression levels of
TNFAIP2 are up-regulated in glioma cell-lines and tissues
compared to non-neoplastic brain tissues. As in other re-
ports, the results of the present study indicated that miR-
184 could regulate TNFAIP2 in glioma cells. The up-
regulated expression of miR-184 in U87 and U251 cells
led to the obvious down-regulation of TNFAIP2 mRNA
and protein expressions. Reducing the expression of miR-
184 resulted in the significant up-regulation of TNFAIP2
mRNA and protein. The IHC results of the nude mice in-
tracerebral transplantation tumors further demonstrated
that U87 cells transfected with miR-184 had reduced
TNFAIP2 compared to the miR-NC groups. The results
confirmed that both TNFAIP2 mRNA and protein expres-
sions were substantially down-regulated by the high ex-
pression of miR-184 in gliomas. In human gliomas,
TNFAIP2 was one of the specific targets of miR-184. The
study’s results showed that the expression level of
TNFAIP2 was higher in human gliomas than in noncan-
cerous brain tissues. Also, miR-184 targeted TNFAIP2
in vitro and in vivo, but it was neither elaborated upon nor
proven whether the high expression of TNFAIP2 led to
the process of invasion and proliferation in gliomas or
whether miR-184 suppressed the survival and invasion of
gliomas by down-regulating the expression of TNFAIP2.The function and mechanism of TNFAIP2 in gliomas
need further investigation.
The present study demonstrated that miR-184 was
markedly down-regulated in human glioma cells and tis-
sues, TNFAIP2 was up-regulated in human glioma cells
and tissues, and TNFAIP2 expression was inversely corre-
lated with miR-184 expression. Also, the overexpression of
miR-184 led to the down-regulation of TNFAIP2, and
miR-184 regulated the expression of TNFAIP2 by binding
to the 3′-UTR of TNFAIP2 mRNA. miR-184 had a signifi-
cant suppressive effect on glioma proliferation, migration,
and invasion. All the experiments showed that miR-184
was a suppressor gene in the malignant procession and
carcinogenesis of gliomas and may be used to develop a
miRNA-based therapeutic strategy against glioma.
Conclusion
The results showed that miR-184 may regulate the ex-
pression of TNFAIP2 by binding to the 3′-UTR of
TNFAIP2 mRNA and affecting its translation in gliomas.
Thus, miR-184 inhibited the progression of gliomas and
may serve as a novel therapeutic target for the treatment
of gliomas.
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